While 84 percent of ophthalmologists recognize that the role of biosimilars in ophthalmology is to keep drug costs down, only 48 percent would prescribe them themselves.
About 48 percent of ophthalmologists said that they feel uncomfortable prescribing them from a clinical standpoint.
Twenty-five percent of ophthalmologists are either not familiar with the FDA approval process for biologics or they believe it’s the same process as other medications, which is not the case.
Two-thirds of ophthalmologists believe that the current FDA biosimilar approval process is enough, and more ophthalmologists feel knowledgeable about biosimilar clinical approval than in 2021.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.